Editorial
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Apr 15, 2019; 10(4): 234-240
Published online Apr 15, 2019. doi: 10.4239/wjd.v10.i4.234
Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun
Spyridon N Karras, Theocharis Koufakis, Pantelis Zebekakis, Kalliopi Kotsa
Spyridon N Karras, Theocharis Koufakis, Pantelis Zebekakis, Kalliopi Kotsa, Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki 55535, Greece
Author contributions: Karras SN and Koufakis T conceived the study, reviewed the literature and drafted the manuscript; Zebekakis P and Kotsa K reviewed the literature and revised the manuscript; all authors approved the final version of the article.
Conflict-of-interest statement: The authors have no conflict of interest to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Spyridon N Karras, MD, PhD, Academic Fellow, Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki 55535, Greece. karraspiros@yahoo.gr
Telephone: +30-693-2412914
Received: February 24, 2019
Peer-review started: February 26, 2019
First decision: March 11, 2019
Revised: March 13, 2019
Accepted: March 26, 2019
Article in press: March 26, 2019
Published online: April 15, 2019
Processing time: 51 Days and 20.8 Hours
Core Tip

Core tip: Adjunctive to insulin therapies in type 1 diabetes (T1D) may have a role in optimizing metabolic control, assisting weight management and reducing glycemic variability. Specific safety issues should be further assessed by future studies, before these therapeutic choices become widely available for T1D management.